Most shifts in healthcare start quietly. Before a therapy gains momentum, before prescribing behavior changes, and before a trend becomes obvious, something usually changes in expert conversations first. The challenge is that these signals do
Most teams have access to KEE insights. They know who the key experts are, what they’re publishing, where they’re speaking, and how active they are. In many cases, they also have dashboards that track engagement
Scientific information doesn’t move in a straight line. A new study, conference presentation, or clinical observation enters a network of experts, where it is discussed, interpreted, and shared across multiple touchpoints.
Most teams recognize a trend only after it shows up in data. By then, it’s already in motion. In healthcare, adoption doesn’t start with prescriptions or performance metrics. It starts earlier, when experts begin to
Product adoption in healthcare usually unfolds gradually. Before prescribing patterns begin to shift, conversations among experts start to evolve. New evidence is discussed at conferences, mechanisms are debated in publications, and clinicians share their perspectives
For years, dashboards have been the standard way Medical Affairs teams monitor expert activity, scientific conversations, and engagement performance. They organize information into clear visuals and reports, helping teams track what is happening across therapeutic
Static expert lists can’t capture shifting influence in today’s fast-moving healthcare environment. With a dynamic KOL database and advanced KOL analysis tools, teams gain real-time insights into expert behavior, sentiment, and emerging KEEs for smarter
Speaker selection has traditionally followed a familiar pattern: identify well-known experts, validate credentials, and build programs around visibility and reputation. While this approach checks many boxes, it often misses the most important question:
Neolytica blends KOL sentiment analysis, behavioral insights, and network mapping to reveal influential local clinicians, improving pharma engagement and strategy.
Medical and commercial teams rarely disagree on objectives. Both want relevant conversations, credible science, and measurable impact. Yet in practice, alignment often breaks down, not because of intent, but because teams are working with partial
Field and medical teams spend countless hours planning who to meet, what to discuss, and how to advance scientific conversations. But despite all this effort, one question keeps coming back:
In medical affairs and field engagement, timing and context often decide the quality of every conversation. You can have the best data, the strongest story, and the right expert, but if the dialogue doesn’t align